IOL Chemicals and Pharmaceuticals Limited
IOLCP.NS
National Stock Exchange of India144.46
INR
+1.50
- -
IOL Chemicals and Pharmaceuticals Limited
IOLCP.NS
(National Stock Exchange of India)
Recent
price
144.46
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- IOL Chemicals and Pharmaceuticals Limited is a prominent Indian pharmaceutical and specialty chemicals manufacturer, serving both domestic and international markets. The company operates through distinct chemical and pharmaceutical divisions. Its pharmaceutical segment focuses on producing a wide array of active pharmaceutical ingredients (APIs), including ibuprofen, paracetamol, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, and gabapentin. These APIs are crucial for treatments targeting conditions such as inflammation, pain relief, fever reduction, diabetes management, anti-platelet therapy, cholesterol regulation, seizure control, hypertension, and proton pump inhibition. Notably, the company is recognized as a significant global producer of Ibuprofen, holding a substantial share of the world market. The chemical division offers specialty industrial chemicals like ethyl acetate, iso butyl benzene, acetyl chloride, and mono chloro acetic acid. These compounds find extensive applications across diverse sectors, including food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, pesticides, and the production of chemical intermediates. IOL Chemicals and Pharmaceuticals Limited, established in 1986, is headquartered in Ludhiana, India, and emphasizes backward integration, innovation, and sustainable manufacturing practices in its operations. The company supplies its high-quality APIs to over 80 countries globally. Recent corporate activities include a consideration of a stock split in late 2024 to enhance share affordability.IOL Chemicals and Pharmaceuticals Limited operates as a significant producer and supplier of both pharmaceutical and chemical products across India and internationally. The company functions through specialized segments catering to distinct industrial requirements. Within its pharmaceutical division, a comprehensive range of active pharmaceutical ingredients (APIs) are manufactured, encompassing products such as ibuprofen, its derivatives like ibuprofen lysinate and ibuprofen sodium, as well as metformin hydrochloride, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gabapentin, levetiracetam, lamotrigine, fenofibrate, and paracetamol. These critical ingredients are utilized in various therapeutic applications, including anti-inflammatory, analgesic, and antipyretic treatments, managing diabetes, anti-platelet aggregation, cholesterol control, anti-convulsant therapy, anti-cholelithic conditions, and as proton pump inhibitors. The company stands out as a major global supplier of Ibuprofen. The specialty industrial chemicals segment provides essential compounds such as ethyl acetate, iso butyl benzene, acetyl chloride, and mono chloro acetic acid, among others. These chemicals are vital components for industries like food processing, flexible packaging, other pharmaceutical manufacturing, textiles, ink production, paint formulation, pesticide manufacturing, and serving as chemical intermediates. Established in 1986, IOL Chemicals and Pharmaceuticals Limited maintains its principal office in Ludhiana, India, and is recognized for its integrated operations, focus on innovation, and commitment to sustainable production methods. The company has a global reach, exporting its high-quality APIs to over 80 nations. In recent strategic developments, the company considered a stock split in late 2024 to improve share accessibility for a broader investor base.